This drug candidate
was recently in-licensed from the Gallo Clinic and Research
Center at the University of California San Francisco. Preclinical
data suggests that NRP388 could significantly reduce the opioid
tolerance effect on patients who are administered opioids
over long periods. Because of the potential linkage between
that effect and iatrogenic addiction, the company believes
that this candidate is its most promising in the field of
chronic pain. If successfully developed, such a drug should
be desirable in both oral and intravenous (IV) formulations.
The company anticipates filing an IND on an IV formulation,
targeting the first half of 2006.